ATXN3 and neurodegenerative disease: Therefore, although many preclinical studies indicate the efficiency of DDR and apoptosis modulation in improving the pathology of neurodegenerative diseases including SCA3, further investigation is undoubtedly needed to confirm target specificity and minimize side effects before their employment for therapeutic intervention.